Nortran Pharmaceutical -NRT.V Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Intrepid1 who wrote (1129)	6/12/1999 10:15:00 PM
From: Wisee	Read Replies (1) of 1185

An article in the Edmonton Journal on May 21/99 caught my attention: F. Hoffman LaRoche (Roche) a Swiss pharmaceutical company has pleaded guilty to price fixing of certain vitamins. They have been fined US$500 million and as a result Roche also faces a number of civil class action lawsuits in the US which could be in the hundred of million dollars. Also Roche's upper level management have been replaced with new management in the past month. I am wondering if any of the above may have contributed to the withdrawal of the agreement by Roche. Be your own judge!! I also understand Nortran's molecules that Roche were experimenting with were very satisfactory. Remember the fundamentals for Nortran remain intact. This is only a temporary setback. Continuing along, Wisee

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next